Related Experiment Video
Updated: Sep 28, 2026
A 3D Quantification Technique for Liver Fat Fraction Distribution Analysis Using Dixon Magnetic Resonance Imaging
Published on: October 20, 2023
MnDPDP enhanced magnetic resonance imaging of focal liver lesions
L J King1, G J C Burkill, E D Scurr
1Department of Radiology, Chelsea and Westminster Hospital, London, UK.
Abstract:
Mangafodipir trisodium (MnDPDP) is a contrast agent for use in magnetic resonance imaging (MRI) of the liver. The agent is taken up by normal hepatocytes resulting in increased signal on T1-weighted imaging, and is excreted in the biliary system. Hepatocyte-containing liver neoplasms such as hepatomas or focal nodular hyperplasia (FNH), take up MnDPDP and demonstrate varying degrees of enhancement. Metastatic liver deposits and primary liver tumours of non-hepatocyte origin do not typically enhance with MnDPDP thus increasing their conspicuity compared with pre-contrast T1-weighted images. Metastases may demonstrate rim enhancement particularly on delayed imaging at 24 h, which can increase their conspicuity, thus allowing better visualization of small lesions. Functional biliary obstruction due to liver metastases can also result in wedge shaped areas of parenchymal enhancement. The MRI features of various focal liver after continuance with lesions following MnDPDP are discussed and illustrated including primary lesions such as hepatoma and secondary metastases.
Insights
Mangafodipir trisodium (MnDPDP) enhances liver MRI scans by highlighting normal hepatocytes and biliary excretion. This contrast agent helps differentiate between cancerous and non-cancerous liver tumors, improving lesion detection.
Area of Science:
- Radiology
- Medical Imaging
- Hepatology
Background:
- Mangafodipir trisodium (MnDPDP) is an MRI contrast agent for liver imaging.
- It is selectively taken up by normal hepatocytes and excreted via the biliary system.
Purpose of the Study:
- To evaluate the utility of MnDPDP in differentiating focal liver lesions using MRI.
- To assess the conspicuity of liver tumors and metastases with MnDPDP contrast enhancement.
Main Methods:
- Administration of MnDPDP contrast agent for liver MRI.
- Analysis of T1-weighted imaging, including pre-contrast and post-contrast phases.
- Evaluation of lesion enhancement patterns, including hepatoma, FNH, and metastases.
Main Results:
- Normal hepatocytes and hepatocyte-containing lesions (hepatoma, FNH) show signal enhancement.
- Non-hepatocyte tumors (metastases) typically do not enhance, increasing their conspicuity.
- Delayed imaging (24h) can reveal rim enhancement in metastases, improving visualization of small lesions.
Conclusions:
- MnDPDP is effective in improving the detection and characterization of focal liver lesions.
- The differential enhancement patterns aid in distinguishing between primary liver cancers and metastases.
- Delayed imaging with MnDPDP can enhance the detection of metastatic liver disease.
